Journal of Cataract & Refractive Surgery
Volume 31, Issue 11 , Pages 2137-2141, November 2005

Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens

From the Cornea Research Foundation of America (M.O. Price) and Price Vision Group (F.W. Price), Indianapolis, Indiana, and Nidek Technologies America (Maclellan), Greensboro, North Carolina, USA

Accepted 27 April 2005.

Purpose

To determine whether gatifloxacin 0.3% ophthalmic solution or moxifloxacin 0.5% ophthalmic solutions are toxic to the corneal epithelium when used with 1 of 2 dosing regimens in healthy human eyes.

Setting

Price Vision Group, Indianapolis, Indiana, USA.

Methods

In this double-masked randomized fellow-eye comparison study, gatifloxacin 0.3% was instilled in 1 eye and moxifloxacin 0.5% in the other eye either 4 times a day for 7 days or hourly for 10 hours. Before and after dosing, all eyes were examined with a slitlamp and the cell layers in the central cornea were evaluated by confocal microscopy. Subject discomfort with study drop instillation was also assessed.

Results

There was no statistically significant increase in the incidence or severity of superficial punctuate keratitis following use of gatifloxacin 0.3% or moxifloxacin 0.5% when instilled 4 times a day for 7 days or hourly for 10 hours. Hourly use of gatifloxacin 0.3% for 10 hours resulted in a mild but statistically significant increase in conjunctival hyperemia (P = .029). Use of moxifloxacin 0.5% resulted in a small but statistically significant deterioration of the corneal epithelial surface as assessed by confocal microscopy (P = .045). The incidence of subject discomfort with study drop instillation was comparable for the 2 antibiotics (P = .67).

Conclusion

Use of ophthalmic solutions of gatifloxacin 0.3% or moxifloxacin 0.5% did not result in clinically significant epithelial toxicity in healthy human corneas after dosing regimens of 4 times a day for 7 days or hourly for 10 hours dosing regimens.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by an unrestricted educational grant from Allergan, Inc., and by the Cornea Research Foundation of America.Clorissa Quillin, Laurie Potrzebowski, and Annette Cooke provided technical and logistic assistance with this clinical study.Dr. Maclellan is employed by Nidek, which sells the Confoscan 3 confocal microscope. No other author has a financial or proprietary interest in material or method mentioned.

PII: S0886-3350(05)00680-2

doi:10.1016/j.jcrs.2005.04.032

Journal of Cataract & Refractive Surgery
Volume 31, Issue 11 , Pages 2137-2141, November 2005